Kinfo
Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

HEPANASDAQHealthcare·US · USD
$0.11
-0.03 (-18.57%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap12.94M USD
Enterprise value10.36M USD
Trailing P/E0.06
Forward P/E-0.01
PEG ratio-0.01
Price / sales0.00
Price / book1.33
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-61.16%
Return on equity-125.64%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-3.19M USD
Diluted EPS-$0.15
Rev. growth (YoY)0.00%
Balance sheet
Total cash1.63M USD
Total debt0.00 USD
Debt / equity0.00
Current ratio3.91
Book value / share-$0.01
Cash flow (TTM)
Operating cash flow-1.59M USD
Levered free cash flow-416.21K USD
Shares & price
Shares outstanding29.12M
Float18.39M
Held by institutions0.00%
Beta1.69
50-day MA$0.11
200-day MA$0.07
52-week high$0.22
52-week low$0.03
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-07-161.101.17+6.36%2026-03-170.420.65+54.76%2026-03-040.060.15+150.00%2026-02-100.961.00+4.17%2024-04-16-131.50-81.23+38.23%
About Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for chronic liver diseases. Its key asset, Rencofilstat, is a potent cyclophilin inhibitor aimed at treating conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma (HCC). Rencofilstat targets multiple molecular pathways involved in liver disease progression, from initial triggers to those impairing liver function. The company leverages its AI-POWR platform for integrative bioinformatic analysis, utilizing both proprietary clinical data and public multi-omic databases to inform drug development. Recently, Hepion has transitioned towards developing and licensing diagnostic tests for diseases including celiac disease, respiratory infections, Helicobacter pylori, and HCC. Incorporated in 2013 and headquartered in Morristown, New Jersey, Hepion holds FDA Fast Track and Orphan Drug designations for Rencofilstat, reflecting its significance in addressing unmet medical needs in liver disease therapeutics.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sireesh Appajosyula Pharm.D.
Employees
2
Headquarters
Morristown, NJ, United States

Frequently asked questions about Hepion Pharmaceuticals, Inc.